R-CHMP regimen
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Synonyms and keywords: Rituximab-Cyclophosphamide-Hydroxydaunorubicin-Marqibo-Prednisone regimen
Overview
Overview
R-CHMP regimen refers to a regimen consisting of rituximab, cyclophosphamide , doxorubicin (hydroxydaunorubicin), vincristine (Marqibo), and prednisone used to treat aggressive non-Hodgkin’s lymphoma.[1]
Regimen
Regimen
RRituximab (Rituxan)
CCyclophosphamide (Cytoxan)
HDoxorubicin (Hydroxydaunorubicin)
MVincristine liposomal (Marqibo)
PPrednisone
References
References
- ↑ 1.0 1.1 Hagemeister F, Rodriguez MA, Deitcher SR, Younes A, Fayad L, Goy A; et al. (2013). “Long term results of a phase 2 study of vincristine sulfate liposome injection (Marqibo(®) ) substituted for non-liposomal vincristine in cyclophosphamide, doxorubicin, vincristine, prednisone with or without rituximab for patients with untreated aggressive non-Hodgkin lymphomas”. Br J Haematol. 162 (5): 631–8. doi:10.1111/bjh.12446. PMID 23802738.
Looking for the patient version?
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH